Categories AlphaGraphs, Earnings, Finance

Highlights of BOK Financial Corporation’s Q4 2022 earnings

Financial services company BOK Financial Corporation (NASDAQ: BOKF) announced results for the fourth quarter of 2022, reporting higher net profit and net interest revenue.

BOK Financial Corporation Q4 2022 earnings infographic

At $352.6 million, net interest revenue was up 27% year-over-year. Net interest margin moved up to 3.54% from 2.52%, mainly reflecting the recent increase in interest rates. At the end of the quarter, the company had total loans of $22.6 billion, up from $20.2 billion recorded a year earlier.  

Net income increased sharply to $168.4 million or $2.51 per share in the fourth quarter from $117.2 million or $1.71 per share in the same period of 2021. During the quarter, BOK Financial repurchased 314,406 shares at an average price of $103.14 per share.

Commenting on the results, the company’s CEO Stacy Kymes said, “This quarter was the highest pre-provision net revenue in our history. We enjoyed loan growth, net interest margin expansion, strong capital levels, and balance sheet liquidity while asset quality remains very strong. We also took actions in the fourth quarter to move toward a more neutral interest rate position.”


Stocks you may like:

Bank of America (BAC) Stock

Wells Fargo (WFC) Stock

JPMorgan Chase (JPM) Stock

Citigroup (C) Stock

Goldman Sachs (GS) Stock

Morgan Stanley (MS) Stock


Most Popular

Nike (NKE) looks set to beat hurdles and build a brighter future

Nike, Inc. (NYSE: NKE) has long been ruling the sportswear market but the company had its share of problems when headwinds like the pandemic and economic slowdown hit the business

Electronic Arts (EA): A few points to keep in mind if you have an eye on this gaming company

Shares of Electronic Arts Inc. (NASDAQ: EA) stayed green on Friday. The stock has dropped 7% over the past three months. The video game industry has been facing challenges as

Petros Pharma is focused on establishing mechanisms for Rx-to-OTC switch: CCO Fady Boctor

Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) is a pharma company focused on identifying, developing, and commercializing therapeutics for men's health issues. It operates mainly through the business segments of Prescription Medications

Add Comment
Viewing Highlight